title: EMMPRIN in gynecologic cancers: pathologic and therapeutic aspects.
abstract: The highly glycosylated transmembrane protein extracellular matrix metalloproteinase inducer (EMMPRIN) is associated with several pathological conditions, including various types of cancers. In different gynecological malignancies, such as ovarian, cervical, and endometrial cancers, EMMPRIN plays significant roles in cell adhesion modulation, tumor growth, invasion, angiogenesis, and metastasis by inducing the production of various molecules, including matrix metalloproteinases and vascular endothelial growth factor. Because of its high level of expression, EMMPRIN can possibly be used as a diagnostic marker of gynecological cancers. Recent studies have showed that targeting EMMPRIN, especially by RNA interference (RNAi) technology, has promising therapeutic potential in basic research on gynecological cancer treatments, which make a platform for the future clinical success. This review study focused on the association of EMMPRIN in gynecological cancers in the perspectives of pathogenesis, diagnosis, and therapeutics.
authors.affiliation: Department of Gynecology, Cangzhou Central Hospital, Cangzhou, 061001, China, ldt2014@hotmail.com.
authors.forename: Dan-tong
authors.initials: DT
authors.lastname: Liu
mesh_terms: D051926:Basigin / Q000096:biosynthesis / Q000235:genetics*; D002448:Cell Adhesion / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005833:Genital Neoplasms, Female / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D006801:Humans; D009361:Neoplasm Invasiveness / Q000235:genetics; D009362:Neoplasm Metastasis; D009389:Neovascularization, Pathologic / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D034622:RNA Interference
chemical_list: C497886:BSG protein, human; D051926:Basigin